Post Profile






Novartis psoriasis drug maintains efficacy after four years: study

ZURICH (Reuters) - Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.
read more

share

Related Posts


Secukinumab showed superior efficacy over etanercept in clearing skin, according to pivotal Novartis Phase III psoriasis results presented at EADV

Health : Medical News Today

Novartis has nnounced the results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, showed superior efficacy to etanercept in moderate-to-severe plaque psoriasis1. Eta...

Novartis says Entresto linked to higher quality of life scores

Health : Reuters: Health

ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday that a new analysis showed its Entresto drug was linked to higher quality of life scores among patients who had been hospitalized with reduced ejection fraction heart failur...

Novartis drug Zykadia gets positive trial results

Health : Reuters: Health

ZURICH (Reuters) - Novartis cancer drug Zykadia showed positive results in a phase III clinical trial in treating patients with a form of lung cancer, the Swiss drugmaker said on Friday.

Novartis says MS drug cut risk of disability advance in study

Health : Reuters: Health

ZURICH (Reuters) - Novartis's investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said on Saturday, citing a new an...

J&J psoriasis drug tops placebo, Humira in late stage study

Health : Reuters: Health

(Reuters) - An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according t...

Comments


Copyright © 2016 Regator, LLC